FDA Investigating Safety of Asthma Drug Xolair

Injected medication may be linked to higher risk of heart attack, stroke, agency says

By Steven Reinberg
HealthDay Reporter

Related Encyclopedia • Acidophilus • Alzheimer's Disease • Aneurysms • Angina Pectoris More... Related Healthscout Videos Shutting Down Tremor. What's Your Stroke IQ? Disaster Heart Attacks Teaching Old Docs New Tricks More... Related Animations • Alzheimer's Disease Video Animation • Angioplasty • Asthma • Coronary Bypass Surgery More... Related Drug Information • Accupril • Actonel • Advair Diskus • Altace More... Related News Articles • New Generation of Healing: Genes to the Rescue • White Women More at Risk for Restless Legs • Deadly Stomach Bug Making Inroads Outside Hospitals • Living With Less TV, More Sweat Boosts Weight Loss More...

THURSDAY, July 16 (HealthDay News) -- The U.S. Food and Drug Administration has begun a safety review of the asthma drug Xolair (omalizumab) after reports of an increased risk of heart attack, abnormal heart rhythm, heart failure and stroke, the agency said Thursday.

Early results from the what's known as the EXCELS trial (Evaluating the Clinical Effectiveness and Long-Term Safety in Patients with Moderate to Severe Asthma) spurred the investigation, the FDA said. The results indicate that Xolair boosts the risk of heart problems among users of the drug compared with nonusers.

Text Continues Below

---

The data from the trial was supplied to the FDA by Genentech, the maker of Xolair. The trial includes some 5,000 people taking the drug and an additional 2,500 people who are not using Xolair, according to the FDA.

Xolair, which is given by injection, is intended for people whose asthma is not controlled by inhaled corticosteroids.

Currently, the FDA is not telling people using Xolair to stop taking the drug. However, the agency believes that patients and doctors should be aware of potential problems when taking Xolair, including the possible risk for heart attack and stroke.

The final results of the study are not expected until 2012, and the FDA pointed out that factors other than the drug could be responsible for the increase in heart attack and stroke seen among users of Xolair.

Genentech spokeswoman Tara Cooper said the preliminary study results are not sufficient to prove the drug causes increased risk for heart attack and stroke.

"Limitations of the existing data preclude a definitive association with Xolair use," Cooper said. "At this time, there is insufficient information for the companies to change their assessment of the benefit-risk profile for Xolair. Physicians should continue to assess whether Xolair is appropriate for their individual patients."

Page:  1 | 2 | Next >>